Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Carsten Utoft Niemann; Mark-David Levin; Julie Dubois; Sabina Kersting; Lisbeth Enggaard; Gerrit J Veldhuis; Rogier Mous; Clemens H. M. Mellink; Johan A Dobber; Christian B. Poulsen; Henrik Frederiksen; Ann Janssens; Ida Schjødt; Ellen C Dompeling; Juha Ranti; Mattias Mattsson; Mar Bellido; Hoa T T Tran; Kazem Nasserinejad; Arnon P. Kater

doi:10.1182/blood.2020008608

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Carsten Utoft Niemann, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Rogier Mous, Clemens H. M. Mellink, Johan A Dobber, Christian B. Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa T T Tran, Kazem Nasserinejad, Arnon P. Kater

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	1117-1120
Number of pages	4
Journal	Blood
Volume	137
Issue number	8
Early online date	7 Oct 2020
DOIs	https://doi.org/10.1182/blood.2020008608
Publication status	Published - 25 Feb 2021

Access to Document

10.1182/blood.2020008608

Cite this

Niemann, C. U., Levin, M.-D., Dubois, J., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., Dobber, J. A., Poulsen, C. B., Frederiksen, H., Janssens, A., Schjødt, I., Dompeling, E. C., Ranti, J., Mattsson, M., Bellido, M., Tran, H. T. T., Nasserinejad, K., & Kater, A. P. (2021). Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 137(8), 1117-1120. https://doi.org/10.1182/blood.2020008608

@article{94bf71813e7d40d082d581fce2e28b0c,

title = "Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia",

author = "Niemann, {Carsten Utoft} and Mark-David Levin and Julie Dubois and Sabina Kersting and Lisbeth Enggaard and Veldhuis, {Gerrit J} and Rogier Mous and Mellink, {Clemens H. M.} and Dobber, {Johan A} and Poulsen, {Christian B.} and Henrik Frederiksen and Ann Janssens and Ida Schj{\o}dt and Dompeling, {Ellen C} and Juha Ranti and Mattias Mattsson and Mar Bellido and Tran, {Hoa T T} and Kazem Nasserinejad and Kater, {Arnon P.}",

note = "Funding Information: The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript. Funding Information: The authors thank all participating patients, local data managers for study coordination and patient data collection, local investigators, and, in particular, the study team at the HOVON Data Center at the Erasmus MC Cancer Institute and the 2 central laboratories at Amsterdam UMC and Rigshospitalet. The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript. The investigators are independent data owners with unrestricted publication rights.",

year = "2021",

month = feb,

day = "25",

doi = "10.1182/blood.2020008608",

language = "English",

volume = "137",

pages = "1117--1120",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "8",

}

Niemann, CU, Levin, M-D, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, GJ, Mous, R, Mellink, CHM, Dobber, JA, Poulsen, CB, Frederiksen, H, Janssens, A, Schjødt, I, Dompeling, EC, Ranti, J, Mattsson, M, Bellido, M, Tran, HTT, Nasserinejad, K & Kater, AP 2021, 'Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia', Blood, vol. 137, no. 8, pp. 1117-1120. https://doi.org/10.1182/blood.2020008608

TY - JOUR

T1 - Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

AU - Niemann, Carsten Utoft

AU - Levin, Mark-David

AU - Dubois, Julie

AU - Kersting, Sabina

AU - Enggaard, Lisbeth

AU - Veldhuis, Gerrit J

AU - Mous, Rogier

AU - Mellink, Clemens H. M.

AU - Dobber, Johan A

AU - Poulsen, Christian B.

AU - Frederiksen, Henrik

AU - Janssens, Ann

AU - Schjødt, Ida

AU - Dompeling, Ellen C

AU - Ranti, Juha

AU - Mattsson, Mattias

AU - Bellido, Mar

AU - Tran, Hoa T T

AU - Nasserinejad, Kazem

AU - Kater, Arnon P.

N1 - Funding Information: The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript. Funding Information: The authors thank all participating patients, local data managers for study coordination and patient data collection, local investigators, and, in particular, the study team at the HOVON Data Center at the Erasmus MC Cancer Institute and the 2 central laboratories at Amsterdam UMC and Rigshospitalet. The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript. The investigators are independent data owners with unrestricted publication rights.

PY - 2021/2/25

Y1 - 2021/2/25

UR - http://www.scopus.com/inward/record.url?scp=85100802986&partnerID=8YFLogxK

U2 - 10.1182/blood.2020008608

DO - 10.1182/blood.2020008608

M3 - Comment/Letter to the editor

C2 - 33027809

SN - 0006-4971

VL - 137

SP - 1117

EP - 1120

JO - Blood

JF - Blood

IS - 8

ER -

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Access to Document

Other files and links

Cite this